Robert Li, MD
Adult Reconstructive Orthopaedic Surgery · Bronx, NYNPI 1255619698
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Stryker accounts for 66.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $746 and has fallen 64.5% since, to $265 in 2025. That places this record below the midpoint for adult reconstructive orthopaedic surgery clinicians in NY, where the typical reported total is $11,547.
Across 52 payments — averaging $46.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$2K
- Acumed LLC$214
- Johnson & Johnson$179
- Amgen$117
- Convatec Inc.$67
- Ferring Pharmaceuticals Inc.$48
- plus $194 from 8 others
Across 1 payment — averaging $139,040 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$139K
What the payments were for
- Travel & lodging$623%
- Food & beverage$2,37797%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 22 | $1,621 |
| Acumed LLC | 3 | $214 |
| Johnson & Johnson(2 entities) | 4 | $179 |
| Amgen(2 entities) | 8 | $117 |
| Convatec Inc. | 4 | $67 |
| Ferring Pharmaceuticals Inc. | 2 | $48 |
| Orthofix Medical, Inc. | 1 | $45 |
| Pacira Therapeutics, Inc. | 2 | $35 |
| Baxter Healthcare | 1 | $27 |
| ERMI LLC | 1 | $24 |
| Boehringer Ingelheim | 1 | $16 |
| Anika Therapeutics, Inc. | 1 | $16 |
| Molnlycke Health Care US, LLC | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,439 in reported general payments places this provider in the 15th percentile of 85 adult reconstructive orthopaedic surgery providers in New York.
See all adult reconstructive orthopaedic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 76 | $19,790 |
| CeftriaxoneCeftriaxone Sodium | 12 | $522 |
| Meloxicam | 40 | $75 |
Paid to pharmacies, not to this prescriber.
Other adult reconstructive orthopaedic surgery in Bronx
- Ronald HuangBronx$7K
- Seth JerabekNew York$7.1M
- Jose RodriguezNew York$3.4M
- Friedrich BoettnerNew York$2.9M
- Jonathan VigdorchikNew York$2.3M
- William LongNew York$1.5M
- Peter SculcoNew York$1.5M
- Roshan ShahNew York$1.3M
- Herbert CooperNew York$1.3M
- Matthew AustinNew York$986K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.